Myron Ignatius, Ph.D.
The University of Texas Health Science Center at San Antonio
|Titles & Positions|
|Institutional & Related Links|
|Grant ID: RR160062|
Recruitment of First-Time, Tenure-Track Faculty Members
Massachusetts General Hospital/Harvard Medical School
May 18, 2016
One of the most common soft-tissue cancers in children mostly affects very young children, and is often deadly if it comes back after treatment.
Embryonal rhabdomyosarcoma (ERMS) is a cancer of skeletal muscle that has a high five-year survival rate (>70%) with early diagnosis and treatment. But if the cancer recurs, it responds poorly. Even for survivors, treatment often causes health problems or other cancers later in life.
How ERMS tumors relapse is the central question driving the research of Myron Ignatius, recruited from Harvard to join the Department of Molecular Medicine and Greehey Children’s Cancer Research Institute at The University of Texas Health Science Center, San Antonio. His research is supported by a First-Time Tenure Track Award from CPRIT.